Constitutively altered frequencies of circulating follicular helper T cell counterparts and their subsets in rheumatoid arthritis

Irene Arroyo-Villa 1, María-Belén Bautista-Caro 1, Alejandro Balsa 1, Pilar Aguado-Acín 1, Mara-Gema Bonilla-Hernán 1, Chamaida Plasencia 1, Alejandro Villalba 1, Laura Nuo 1, Amaya Puig-Krger 2, Emilio Martín-Mola 1 and María-Eugenia Miranda-Carbó 1*

Abstract

Introduction: Circulating CD4 T cells expressing CXCR5, ICOS and/or PD-1 are counterparts of follicular helper T cells (Tfh). There are three subpopulations of circulating Tfh (cTfh): CXCR5 + CXCR3 + CCR6- (Tfh-Th1), CXCR5 + CXCR3-CCR6- (Tfh-Th2) and CXCR5 + CXCR3-CCR6+ (Tfh-Th17). Our objective was to study the B cell helping capacity of cTfh subsets, and examine their frequency in Rheumatoid Arthritis (RA) patients, together with the frequency of circulating plasmablasts (CD19 + CD20-CD38high).

Methods: Peripheral blood was drawn from RA patients with active disease (RA-a, DAS28 >2.6) (n = 17), RA in remission (RA-r, DAS28 <2.6) (n = 17) and healthy controls (HC) (n = 34). cTfh and plasmablast frequencies were determined by flow cytometry. Cocultures of sorted CD4 + CXCR5+ T cell subpopulations were established with autologous CD19 + CD27- naive B cells of HC, and concentrations of IgG, A and M were measured in supernatants.

Results: Isolated Tfh-Th2 and Tfh-Th17 but not Tfh-Th1 cells, induced naive B cells to secrete IgG and IgA. The frequency of CXCR5+ cells gated for CD4+ T cells was not different among HC, RA-a and RA-r. In contrast, both RA-a and RA-r patients demonstrated an increased frequency of CD4 + CXCR5 + ICOS+ T cells and augmented (%Tfh-Th2 + %Tfh-Th17)/%Tfh-Th1 ratio as compared with HC. In addition, RA-a but not RA-r patients, showed an increased frequency of circulating plasmablasts.

Conclusion: Both RA-a and RA-r patients demonstrate an increased frequency of cTfh and overrepresentation of cTfh subsets bearing a B cell helper phenotype, suggesting that altered germinal center dynamics play a role in RA pathogenesis. In contrast, only RA-a patients show an increased proportion of circulating plasmablasts.

Introduction

Rheumatoid Arthritis (RA) is a systemic autoimmune condition characterized by chronic joint inflammation. B cells actively participate in its pathogenesis not only through the production of high-affinity and class-switched autoantibodies [1-3]: alterations in the capacity of B cells to present antigen, secrete cytokines, and modulate T cell function, are also implicated in RA [1].

Follicular helper T cells (Tfh), a major subset of effector T cells, promote B cell maturation and antibody production [4-9]. They are characterized by the expression of the transcription factor BCL-6, by their surface phenotype (CD4 + CXCR5 + ICOS + PD-1+) and their cytokine profile (IL-21, IL-10, IL-17) [4-10]. Tfh cells play an important role in the pathogenesis of autoimmunity [11], and increased numbers have been described in murine models of systemic lupus erythematosus (SLE) [11-13] and inflammatory arthritis [14]; in fact, strategies directed at reducing Tfh cell generation in these animal models seem to ameliorate disease manifestations [13,15].

Classical Tfh cells are located in secondary lymphoid organs [4-9], which prevents their routine study in human patients. Several reports have subsequently described circulating populations of CD4 T cells that express CXCR5...
and display both phenotypic and functional features of true Tfh cells [16-20]. Increased frequencies of circulating Tfh cell counterparts (cTfh) have been associated with autoimmune diseases such as SLE [16,20], Sjogren’s Syndrome [21], autoimmune thyroiditis [22], chronic active hepatitis [23] and myasthenia gravis [24]. To date, only a few articles on cTfh cells in RA have been published and results are discordant among them [20,25-28].

Moreover, recent studies have suggested that distinct subpopulations of cTfh cells have been described, according to the differential expression of the chemokine receptors CXCR3 and CCR6 on CD4+ CXCR5+ T cells [17]. An altered balance of these cTfh subsets is associated with autoimmunity in children with juvenile dermatomyositis [17] and in adult patients with SLE [29] but to our knowledge has not been investigated in RA.

Therefore, our objective was to study the frequency of cTfh and cTfh cell subsets together with the frequency of circulating plasmablasts (CD19+CD20-CD38high B cells), in patients with RA. We observed that both RA patients with active disease and RA patients with inactive disease demonstrate an increased frequency of cTfh (CD3+CD4+CXCR5+ICOS+) together with an overrepresentation of cTfh subsets bearing a phenotype associated with B cell helping capacity (CD3+CD4+CXCR5+CXCR3-CCR6+ and CD3+CD4+CXCR5+CXCR6-CCCR3-). In contrast, only RA patients with active disease show an increased proportion of circulating plasmablasts.

### Methods

**Ethics statement**
The study was approved by the Hospital La Paz - IdiPAZ Ethics Committee, and all subjects provided written informed consent according to the Declaration of Helsinki.

**Patients**
Peripheral blood was obtained from 34 RA patients with established disease and from 34 age- and sex-matched healthy controls (HC). RA patients fulfilled at least four 1987 American College of Rheumatology criteria [30], and were receiving non-biological disease-modifying anti-rheumatic drugs (DMARDs) with or without low-dose prednisone. Among RA patients, 17 were in remission as defined by a disease activity in 28 joints (DAS28) score <2.6 (RA-r) and 17 had active disease defined by a DAS28 score >2.6 (RA-a) [31]. All patients tested positive for either rheumatoid factor (RF) or anti-citrullinated peptide antibodies (ACPA), and all of them were receiving methotrexate. Clinical data are summarized in Table 1.

### Isolation of CD4+ T cells and B cells from human peripheral blood

Peripheral blood mononuclear cells (PBMCs) were separated immediately after blood sample collection, by Ficoll-Hypaque (GE Healthcare Biosciences AB, Uppsala, Sweden) density gradient centrifugation. CD4+ T or B cells were purified from freshly isolated PBMCs by exhaustive immunomagnetic negative selection in an Automacs (Miltenyi Biotec, Bergisch Gladbach, Germany), using the CD4+ T Cell Isolation Kit or the B Cell Isolation Kit II from Miltenyi Biotec. Sorted peripheral blood Tfh-Th1, Tfh-Th2 or Tfh-Th17 cells were >98% pure. CD4+CXCR5+ were selected from total CD4+ T cells using PE-labeled CXCR5 microbeads (Miltenyi Biotec). Subsequently, cTfh subpopulations were sorted from CD4+CXCR5+ T cells in a FACSVantage SE flow cytometer (BD Biosciences, San Jose, CA, USA) after staining isolated CD4+CXCR5+ T cells with CXCR3 and CCR6. Sorting was directed to isolating CXCR5+CXCR3+CCR6- T cells (Tfh-Th1 cells), CXCR5+CXCR3-CCR6- T cells (Tfh-Th2 cells) and CXCR5+CXCR3-CCR6+ T cells (Tfh-Th17 cells).

Nave (CD19+CD27-) B cells were selected from total CD19+B cells by negative selection using CD27+microbeads (Miltenyi Biotec). T and B cell subpopulations were >98% pure and used immediately after isolation.

### Results

### Table 1 Clinical characteristics of RA-a and RA-r patients

| Variable                                      | RA-a (n = 17) | RA-r (n = 17) |
|------------------------------------------------|--------------|--------------|
| Age, years, median (IQR)                       | 57 (54 to 63.5) | 53.5 (44 to 57.5) |
| Female, n (%)                                 | 16 (94)      | 13 (76.5)    |
| Disease duration, years, median (IQR)         | 12.5 (6 to 20) | 10 (6 to 16.5) |
| Disease activity in 28 joints (DAS28) score, median (IQR) | 3.4 (3 to 4.4) | 2 (1.7 to 2.4) |
| Rheumatoid factor-positive, n(%)              | 16 (94)      | 16 (94)      |
| Anti-citrullinated peptide antibodies-positive, n(%) | 14 (82)      | 14 (82)      |
| Methotrexate, n(%)                            | 17 (100)     | 17 (100)     |
| Prednisone ≤5 mg/day, n(%)                    | 11 (65)      | 4 (24)       |
| Leflunomide, n(%)                             | 2 (12)       | 3 (18)       |
| Hydroxychloroquine, n(%)                      | 2 (12)       | 4 (24)       |

RA-a: RA patients with active disease (DAS28 >2.6); RA-r: RA patients in remission (DAS28 <2.6) [31].

Arroyo-Villa et al. Arthritis Research & Therapy 2014, 16:500
http://arthritis-research.com/content/16/6/500

Page 2 of 8
IgA and IgM were measured in co-culture supernatants by ELISA.

**Flow cytometry**

The frequency and phenotype of Tfh-like cells and plasmablasts present in the peripheral blood of RA patients and HC was assessed by flow cytometry in a FACSCalibur flow cytometer using CellQuest software (BD Biosciences), after staining freshly isolated PBMCs with antibodies directed against surface phenotypic markers. Fluorochrome-conjugated mAbs from BD Pharmingen (San Diego, CA, USA) were used to examine the expression of CD3, CD4, CD8, CXCR5, ICOS, PD-1, CCR6, CXCR3, CD19, CD20, and CD38.

**ELISA**

Cell-free co-culture supernatants were collected and stored at −80°C. The concentrations of immunoglobulins were measured by ELISA. In brief, 96-well plates (MaxiSorp, Thermo Fisher Scientific, Waltham, MA, USA) were coated overnight at 4°C with 10 μg/ml mouse monoclonal anti-human IgG, IgA or IgM (AbD Serotec, Munich, Germany), and subsequently blocked with 2% BSA/PBS. Standard curves of human IgG, IgA or IgM (Sigma-Aldrich) together with culture supernatants diluted in 2% BSA/PBS were incubated for 3 hours at room temperature, washed and developed with horseradish peroxidase-conjugated goat anti-human IgG, IgA or IgM (AbD serotec) followed by TMB substrate solution (Pierce Biotechnology, Rockford, IL, USA). Absorbance was measured at 450 nm in a Synergy H4 Hybrid Multi-Mode Microplate Reader (BioTec Instruments, Inc., Winooski, VT, USA).

**Statistical analysis**

Comparison between groups was by Mann-Whitney or Kruskal-Wallis test. When appropriate, Bonferroni correction for multiple comparisons was applied. Correlations were analyzed using Spearman's rank correlation coefficient. All analyses were performed using Prism version 5.0 software (GraphPad Software, San Diego, CA, USA).

**Results**

**Functional capacity of cTfh subpopulations**

Our first goal was to examine the functional capacity of sorted peripheral blood Tfh-Th1, Tfh-Th2 and Tfh-Th17 cells. In co-cultures with autologous Tfh-Th2 or Tfh-Th17 cells, naive B cells secreted both IgG and IgA, together with IgM (Figure 1). In contrast, naive B cells co-cultured with Tfh-Th1 cells did not produce detectable IgG or IgA but only low amounts of IgM (Figure 1). This indicates that among circulating CXCR5+ T cells, only Tfh-Th2 and Tfh-Th17, but not Tfh-Th1 cells, are able to induce maturation of naive B cells, which is consistent with results published by Morita et al. [17].

**An increased frequency of circulating Tfh counterparts is apparent in the peripheral blood of RA patients with active or inactive disease**

We then sought to examine the expression of Tfh phenotypic surface markers on CD4+ T cells present in the peripheral blood of RA-a or RA-r patients. Importantly, the absolute numbers of circulating CD4+ T cells were not different among the three studied groups (mean ± standard error of the mean (SEM), 1,141.0 ± 142.8 · 10^3 CD4+ T cells/ml in RA-a versus 950.6 ± 132.3 in RA-r, versus 1,024.2 ± 163.8 in HC, \( P >0.1 \)). In addition, the frequency of CXCR5+ cells among circulating CD4+ T lymphocytes was not different in RA-a or RA-r patients as compared with HC (Figure 2A). In contrast, the frequencies of circulating CD4+ CXCR5+ ICOS+ T cells, which are considered as circulating counterparts of classical Tfh cells [16,18,19], were significantly increased both in RA-a and RA-r patients (Figure 2B). Among RA patients, there was no correlation between disease activity parameters and frequency of cTfh (Figure 2C).

**RA patients with active or inactive disease demonstrate an altered balance of cTfh subsets**

RA patients with active or inactive disease demonstrated a decreased frequency of circulating Tfh-Th1 cells together with an increased frequency of Tfh-Th17 cells, whereas the frequency of Tfh-Th2 cells tended to be elevated but was not statistically different from HC (Figure 3A). Furthermore, the sum of %Tfh-Th2 plus %Tfh-Th17 cells, and the ratio (%Tfh-Th2 + %Tfh-Th17)/%Tfh-Th1 were
significantly higher in RA-a or RA-r patients as compared with HC (Figure 3B).

That is, both RA-a and RA-r patients demonstrated a relative overabundance of Tfh cell subsets bearing a B cell helper phenotype. Among RA patients, there was no correlation between disease activity parameters and the observed proportions of cTfh subset or cTfh subset ratios (Figure 3C).

RA patients with active disease demonstrate an increased frequency of circulating plasmablasts

The absolute number of circulating CD19+ cells was not different in RA patients with active (RA-a) or inactive disease (RA-r) as compared with controls (HC). Histograms represent CXCR5 expression in cells gated for CD3 and CD4. (B) Increased frequency of circulating Tfh counterparts in RA-a or RA-r patients, defined as CD4 + CXCR5 + ICOS+ T cells. Representative dot plots demonstrate ICOS and CXCR5 expression in cells gated for CD3 and CD4. (C) Relationship between cTfh proportions and disease activity as determined by disease activity in 28 joints (DAS28) score [31]. In A and B, box and whiskers plots represent the median, interquartile range, maximum and minimum values calculated from the 17 RA-a patients, 17 RA-r patients and 34 HC that were studied. *P <0.01 versus HC.

Discussion

The association of RA with high-affinity, class-switched autoantibodies [1-3], indicates the implication of B helper T cells in disease pathogenesis and therefore we deemed it interesting to study cTfh biology in this condition.

It is herein described that among circulating CD4 + CXCR5+ T cells, only sorted Tfh-Th2 and Tfh-Th17 but not Tfh-Th1 cells, display functional properties of classical Tfh present in the germinal centers of secondary lymphoid organs: Tfh-Th2 and Tfh-Th17 but not Tfh-Th1 cells, had the capacity to promote maturation and induce isotype switching of naive B cells, as previously reported by Morita et al. [17]. In addition, we observed that not only RA patients with active disease but also RA patients in remission, demonstrate an increased frequency of cTfh defined as CD4 + CXCR5 + ICOS+ T cells [16,18,19], together with an overrepresentation of (%Tfh-Th2 + %Tfh-Th17)/%Tfh-Th1 cells, (Figure 4B). Among RA patients, there was no correlation between disease activity parameters and proportions of circulating plasmablasts (Figure 4C).
cTfh subsets bearing a B cell helper phenotype (Tfh-Th2 and Tfh-Th17). The augmented CD4+CXCR5+ICOS+ T cell proportions are not attributable to the presence of activated T cells in peripheral blood; although CXCR5 is typically upregulated upon in vivo T cell activation [32], total CD4+CXCR5+ T cells themselves were not increased in our RA patients with active or inactive disease.

Therefore, this constitutive overabundance of cTfh in RA seems related to disease phenotype and pathogenic mechanisms but not to RA disease activity, as has been
reported in patients with SLE [16]: Simpson et al. described an expansion of cTfh in a subset of SLE patients with severe disease, which does not vary with time, modifications in disease activity or treatment [16]. In this context, it has been proposed that increased numbers of cTfh can be a signature of human immune-mediated diseases [19]. In fact, a causal relation between accumulation of Tfh cells and autoimmunity has been demonstrated in mice homozygous for the san allele of Roquin (Roquinsan/san), a protein regulator of mRNA stability [33]. Roquin represses ICOS mRNA post-transcriptionally, and homozygosity for its san allele mediates ICOS overexpression and generation of Tfh cells [13,33]. Roquinsan/san mice demonstrate increased numbers of Tfh cells together with aberrant GC formation and positive selection of pathogenic high-affinity autoantibodies, resulting in a lupus-like phenotype [13,33]. Furthermore, abrogating Tfh cell generation prevents lupus development in the Roquinsan/san mice, and transfer of Tfh cells from these mice induces the spontaneous formation of GCs [13].

Conversely, patients with loss-of-function mutations in CD40L, NEMO, STAT3, IL-21R or BTK and patients with gain-of-function mutations in STAT1, demonstrate a severely impaired generation of germinal centers together with decreased circulating CD4+ CXCR5+ T cells [34], reinforcing the notion that cTfh numbers are a reflection of the pool of classical Tfh in lymphoid organs.

The recent description by Morita et al. of three different subsets of circulating CD4+ CXCR5+ T cells with distinct functional properties [17] sheds new light into the biology of Tfh and their pathogenic implication in autoimmune conditions. Of note, it has been reported that among circulating Tfh cells, the Tfh-Th17 subset is most significantly reduced in all immune deficiencies above mentioned [34], indicating the importance of these cells as B cell helpers. In this context, Tfh-Th17 was the most significantly elevated Tfh subset in our RA patients, which further suggests their leading role in promoting autoantibody production.

Of note, altered proportions of circulating Tfh subsets in patients with juvenile dermatomyositis (JDM) seem to be associated with disease activity [17], which contrasts with findings in our RA patients. This suggests that the mechanisms leading to an altered regulation of Tfh cell subset differentiation may be different in JDM and RA.

Interestingly, we observed that whereas RA-a patients show an increased frequency of circulating plasmablasts, the frequency of circulating plasmablasts in RA-r was not different from controls. This parallels reported observations indicating that response to treatment in RA is associated with a reduction in the titters of RF and/or ACPA, whereas RA patients who do not respond to treatment maintain antibody levels comparable to those found at baseline [35,36]. Of note, despite a significant reduction of RF and/or ACPA levels associated with therapeutic response, seropositive RA patients rarely become seronegative, indicating the persistence of a constitutive autoimmune alteration [35,36].

A reason for the finding of normal circulating plasmablasts in the presence of elevated cTfh proportions in
RA-r patients is not readily apparent to us. We can only speculate that, in patients who respond and achieve remission, treatment with non-biological DMARDs may block the action of constitutively increased Tfh cell numbers on B cell biology, thereby preventing the generation of increased proportions of plasmablasts. Conversely, in RA patients who do not achieve a complete response to DMARDs, these drugs would not be able to modify the function of Tfh. Alternatively, plasmablast generation through the extrafollicular pathway could account for the discordance between cTfh and plasmablast numbers in patients with active or inactive disease [37,38].

Conclusions
In summary, we have described a constitutively increased frequency of cTfh together with an overrepresentation cTfh subsets bearing a B cell helper phenotype in RA. This indicates that excessive Tfh cell generation and altered germinal center dynamics may play a role in the pathogenesis of this condition. In addition, it points to modifications of Tfh effector molecules or Tfh subset balance as future therapeutic targets in RA.

Abbreviations
ACPA: anti-citrullinated peptide antibodies; BSA: bovine serum albumin; cTfh: circulating Tfh; DAS28: disease activity in 28 joints; ELISA: enzyme-linked immunosorbent assay; FCS: fetal calf serum; HC: healthy controls; mAb: monoclonal antibody; PBMC: peripheral blood mononuclear cell; PBS: phosphate-buffered saline; RA: rheumatoid arthritis; RA-a: patients with active rheumatoid arthritis; RA-r: patients with rheumatoid arthritis in remission; RF: rheumatoid factor; SEM: standard error of the mean; SLE: systemic lupus erythematosus; Tfh: Follicular helper T cells; Tfh-Th1 cells: CXCR5+ CXCR3-CCR6- T cells; Tfh-Th17 cells: CXCR5+ CXCR3-CR6+ T cells; Tfh-Th2 cells: CXCR5+ CXCR3-CR6- T cells.

Competing interests
The authors declare that they have no competing interests.

Authors contributions
IAV and MBBC participated in the design of the study, carried out the experiments, performed the statistical analysis and helped to draft the manuscript; AB, PAA, MGBH, CP, AV and LN participated in the acquisition and analysis of data and helped to revise the manuscript; AB and EMM participated in the analysis and interpretation of data and revised the manuscript critically for important intellectual content; MEMC conceived the study, participated in its design, coordination, analysis and interpretation of data, wrote the manuscript, and takes responsibility for the integrity of the data analysis, and final approval of the manuscript. All authors read and approved the final manuscript.

Acknowledgements
This work was supported by Fundación de Investigación Sanitaria: FIS (grant number PI13/000884, from Ministerio de Economía y Competitividad/Instituto de Salud Carlos III [MINECO/ISCIII], by RETICS Program (RD12/009/0012) (RIER) from MINECO/ISCIII, (http://www.idi.mineco.gob.es/portal/site/MICINN, http://www.isciii.es); and by Comunidad Autonoma de Madrid/Fondo Europeo de Desarrollo Regional RAPHYME (www.madrimasd.org). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author details
1Department of Rheumatology, Hospital Universitario La Paz-IdiPaz, Paseo de La Castellana, 261, 28046 Madrid, Spain. 2Hospital General Universitario Gregorio Marañon, Calle Doctor Esquerdo, 46, 28007 Madrid, Spain.

Received: 23 July 2014 Accepted: 27 November 2014
Published online: 05 December 2014

References
1. Silverman GJ, Carson DA: Roles of B cells in rheumatoid arthritis. Arthritis Res Ther 2003, 5(5):51-56.
2. Ioan-Facsinay A, Willeme A, Robinson DB, Peschken CA, Markland J, der Vaart WD, Elias B, Minard HA, Nevikvik M, Fritzler MJ, Toes RE, Huizinga TW, El-Gabalawy HS: Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum 2008, 58:3000-3008.
3. Verpoort KN, Jol-van deZijde CM, Papendrecht-van de Voort EA, Ioan-Facsinay A, Drijfhout JW, Van Tol MJ, Breedveld FC, Huizinga TW, Toes RE: Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum 2006, 54:3799-3808.
4. Craft JE: Follicular helper T cells in immunity and systemic autoimmunity. Nat Rev Rheumatol 2012, 8:337-347.
5. Fazilleau N, Mark L, McHeyzer-Williams LJ, McHeyzer-Williams MG: Follicular helper T cells: lineage and location. Immunity 2009, 30:314-325.
6. Breitfeld D, Ohi L, Kremmer E, Elilwert J, Sallusto F, Lipp M, Frster R: Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med 2000, 192:1545-1552.
7. Schaerl P, Willmann K, Lang AB, Lipp M, Loetscher P, Moser B: CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med 2000, 192:1553-1562.
8. Kim CH, Rott LS, Clark-Lewis I, Campbell DJ, Wu L, Butcher EC: Sub specialization of CXCR5+ T cells: B helper activity is focused in a germinal center-localized subset of CXCR5+ T cells. J Exp Med 2001, 193:1273-1281.
9. Crotty S: Follicular helper CD4 T cells (THF). Annu Rev Immunol 2011, 29:521-563.
10. Bauquet AT, Jin H, Paterson AM, Mitsdoerffer M, Ho IC, Sharpe AH, Kuchroo VK: The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular helper T cells and TH-17 cells. Nat Immunol 2009, 10:167-175.
11. Vinuea CG, Cook MC, Angelucci C, Athanasopoulos V, Ruiz L, Hill KM, Yu D, Domascenetz H, Whittle B, Lambe T, Roberts IS, Copley RR, Bell JI, Cornall RJ, Goodnow CC: A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 2005, 435:452-458.
12. Subramanian S, Tuset K, Li QZ, Wang A, Tian XH, Zhou J, Schulz RA, Wakeland KE: A TIR7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci USA 2006, 103:9970-9975.
13. Linterman MA, Rigby RJ, Wong RK, Yu D, Brink R, Cannons JL, Schwartzberg PL, Cook MC, Walters GD, Vinuea CG: Follicular helper T cells are required for systemic autoimmunity. J Exp Med 2009, 206:561-576.
14. Ji Y, Kim HJ, Yu DH, Bae KB, Park SJ, Yi JK, Kim N, Park SJ, Oh KB, Hwang SS, Lee S, Kim SH, Kim MO, Lee JW, Ryoo ZY: Enforced expression of roquin protein in T cells exacerbates the incidence and severity of experimental arthritis. J Biol Chem 2012, 287:42269-42277.
15. Hont JE, Caplan L, Geth AI, Schwartzberg PL, Peng SL: SH2D1A regulates T-dependent humoral autoimmunity. J Exp Med 2004, 200:261-266.
16. Simpson N, Gatenby PA, Wilson A, Malik S, Fulcher DA, Tangye SG, Manok H, Vyse TJ, Roncador G, Huttley GA, Goodnow CC, Vinuea CG, Cook MC: Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum 2010, 63:324-334.
17. Manera R, Schmitt N, Bentebebel SE, Ranganathan R, Bourdey L, Zuzuvia G, Fouchet E, Dulliers M, Oh S, Sabaghiabaei N, Lavacchio EM, Punaro M, Pascual V, Banchereau J, Ueno H: Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity 2011, 34:108-121.
18. Chevalier N, Jarrossay D, Ho E, Avery DT, Ma CS, Yu D, Sallusto F, Tangye SG, Mackay CR: CXCR5 expressing human central memory CD4 T cells and
their relevance for humoral immune responses. J Immunol 2011, 186:5556-5568.
19. Vinuesa CG, Cook MC: Blood relatives of follicular helper T cells. Immunity 2011, 34:10-12.
20. He J, Tsai LM, Leong YA, Hu X, Ma CS, Chevalier N, Sun X, Vandenberg K, Rockman S, Ding Y, Zhu L, Wei W, Wang C, Ramovecki A, Berz GT, Ghali JR, Cook MC, Reminton DS, Vollarte A, Schwartzberg PL, Mackay F, Brink R, Tangye SG, Vinuesa CG, Mackay CR, Li Z, Yu D: Circulating precursor CCR7(lo)PD-1(hi) CXCR5+ CD4+ T cells indicate Thf cell activity and promote antibody responses upon antigen reexposure. Immunity 2013, 39:770-781.
21. Szabo K, Papp G, Barath S, Gyimesi E, Santoyo A, Zeher M: Follicular helper T cells may play an important role in the severity of primary Sj?gren's syndrome. Clin Immunol 2013, 147:55-104.
22. Zhu C, Ma J, Liu Y, Tong J, Tian J, Chen J, Tang X, Xu H, Lu L, Wang S: Increased frequency of follicular helper T cells in patients with autoimmune thyroid disease. J Clin Endocrinol Metab 2012, 97:943-950.
23. Feng J, Lu L, Hao C, Qin L, Zhao P, Wang J, Li W, Shi X, Wang S: Increased frequency of circulating follicular helper T cells in patients with immune-active chronic hepatitis B. PLoS One 2011, 6:e21698.
24. Luo C, Li Y, Liu W, Feng H, Wang H, Huang X, Qiu L, Ouyang J: Expansion of circulating counterparts of follicular helper T cells in patients with myasthenia gravis. J Neuromuscul Disord 2013, 256:55-61.
25. Chébara A, Bennett SC, Moneau D, Bowness P, Luqumani RA, Cornall RJ: The phenotype of circulating follicular-helper T cells in patients with rheumatoid arthritis defines CD200 as a potential therapeutic target. Clin Dev Immunol 2012, 2012:948218.
26. Ma J, Zhu C, Ma B, Tian J, Baidoo SE, Mao C, Wu W, Chen J, Tong J, Yang M, Xiao Z, Xu H, Lu L, Wang S: Increased frequency of circulating follicular helper T cells in patients with rheumatoid arthritis. Clin Dev Immunol 2012, 2012:927480.
27. Liu R, Wu Q, Su D, Che N, Chen H, Deng L, Chen J, Chen W, Li X, Sun L: A regulatory effect of IL-21 on T follicular helper-like cell and B cell in rheumatoid arthritis. Arthritis Res Ther 2012, 14:R255.
28. Wang J, Shan Y, Jiang Z, Feng J, Li C, Ma L, Jiang Y: High frequencies of activated B cells and follicular helper T cells are correlated with disease activity in patients with new onset rheumatoidarthritis. Clin Exp Immunol 2013, 174:212-220.
29. Le Coz C, Joublin A, Pasquali JL, Korganow AS, Dumortier H, Monneaux F: Circulating Tfh subset distribution is strongly affected in lupus patients with an active disease. PLoS One 2013, 8:e73519.
30. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:331-340.
31. Prevoz ML, Van t Hof MA, Kuper HH, Van Leeuwen MA, Van de Putte LB, Van Riel PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:84-48.
32. Amiel KM, McHeyzer-Williams LJ, Ngu VN, McHeyzer-Williams MG, Oyster JG: In vivo-activated CD4 T cells upregulate CXC chemokine receptor 5 and reprogram their response to lymphoid chemokines. J Exp Med 1999, 190:1123-1134.
33. Yu D, Tan AH, Hu X, Athanasopoulos V, Simpson N, Silva DG, Hutmoff A, Giles KM, Leedman PJ, Larm KP, Goodnow CC, Vinuesa CG: Roquin represses autoimmune by limiting inducible T-cell co-stimulator messenger RNA. Nature 2007, 450:399-403.
34. Vinuesa CG, Fagarasan S, Dong C: New territory for T follicular helper cells. Immunity 2013, 39:417-420.
35. Mikuls TR, O'Dell JR, Stoner JA, Parish LA, Arend WP, Norris JM, Hekler WV: Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum 2004, 50:3776-3782.
36. Bos WH, Baltedds GM, Wolterink GJ, de Koning MH, van de Stadt RJ, van Schaardenburg D, Dijkmans BA, Nurshomved MT: Differential response of the rheumatoid factor and anticitrullinulated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J Rheumatol 2008, 35:1972-1977.
37. Sweet RA, Cullen JL, Shlomchik MJ: Rheumatoid factor B cell memory leads to rapid, switched antibody-forming cell responses. J Immunol 2013, 190:1974-1981.
38. Weisel F, Weilman U, Winkler TH: Autoreactive B cells get activated in extrafollicular sites. Eur J Immunol 2007, 37:3330-3333.